Clinical Study

Lae002int2001- An Open-Label Randomized Active-Controlled Phase II Clinical Study To Assess The Efficacy And Safety Of Afuresertib Plus Paclitaxel Versus Paclitaxel In Patients With Platinum-Resistant Ovarian Cancer

Posted Date: Nov 24, 2020

  • Investigator: Thomas Herzog
  • Specialties: Cancer, Gynecologic Oncology, Oncology, Ovarian Cancer
  • Type of Study: Drug

This is an Open Label Randomized Active Controlled Phase II Clinical Study assessing the efficacy and safety of afuresertib plus paclitaxel versus paclitaxel in patients With platinum-resistant ovarian cancer. Efficacy will be measured by determining the rate of progression free survival.


To Be Eligible: Confirmed High Grade Serous Oc, Endometroid Oc, Or Ovarian Clear Cell Carcinoma, Received Prior Treatments With Bevacizumab Followed By Disease Progression, Or Contraindiction To Bevacizumab, Ecog 0-1, Life Expectancy >6 Months, No Other Active Cancer Within 3 Years, No Hypersensitivity To Study Drugs Or Excipients, No Co-Morbidity Deemed Severe By The Pi


Ovarian Cancer

For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.